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Background & aims 
 
Proton pump inhibitors (PPI) are among the top ten most widely used drugs in the world. 
PPI use has been associated with an increased risk of enteric infections, most notably 
Clostridium difficile. The gut microbiota plays an important role in enteric infections, 
by resisting or promoting colonization by pathogens. In this study, we investigated the 




The gut microbiota composition of 1815 individuals, spanning three cohorts, was 
assessed by tag-sequencing of the 16S rRNA gene. The difference in microbiota 





211 of the participants were using PPI at the moment of stool sampling. PPI use is 
associated with a significant decrease in Shannon’s diversity and with changes in 20% of 
the bacterial taxa (FDR<0.05). Multiple oral bacteria were overrepresented in the faecal 
microbiota of PPI-users, including the genus Rothia (P=9.8x10-38). In PPI users we observed 
a significant increase in bacteria: genera Enterococcus, Streptococcus, Staphylococcus and 




The differences between PPI users and non-users observed in this study are consistently 
associated with changes towards a less healthy gut microbiota. These differences are 
in line with known changes that predispose to C. difficile infections and can potentially 
explain the increased risk of enteric infections in PPI users. On a population level, the 





What is already known about this subject: 
• PPI use is associated with increased risk of enteric infections, in particular  
 with a 65% increase in incidence of Clostridium difficile infection. 
• PPI is one of the most commonly used drugs.  
• Changes in the gut microbiota can resist or promote the colonization of  
 enteric infections.    
 
What are the new findings: 
• PPI use is associated with decreased bacterial richness and profound  
 changes in the gut microbiota: 20% of the identified bacteria in this study  
 showed significant deviation.  
• Oral bacteria and potential pathogenic bacteria are increased in the gut  
 microbiota of PPI users.  
• On the population level we see more microbial alterations in the gut  
 associated with PPI use than with antibiotics or other drug use.  
 
How might it impact on clinical practice in the foreseeable future? 
• Given the widespread use of PPI, the morbidity and mortality associated with  
 enteric infections, and the increasing number of studies investigating the  
 microbiota, both healthcare practitioners and researchers should take into  








Proton pump inhibitors (PPI) are among the top ten most widely used drugs in the world. 
In 2013, 7% of the population of the Netherlands used omeprazole. In the same year, 
esomeprazole was the second largest drug in terms of revenue in the United States.1,2 PPI 
are used to treat gastro-oesophageal reflux disorder (GORD) and to prevent gastric and 
duodenal ulcers.3,4 Of the general population, 25% report having heartburn at least once a 
month, explaining the large demand for PPI.4 Nevertheless, PPI are frequently prescribed 
or taken for long periods without evidence-based indication.5,6 
 
PPI use has been associated with increased risk of enteric infections.5,7–9 A meta-
analysis of 23 studies, comprising almost 300,000 patients, showed a 65% increase 
in the incidence of Clostridium difficile-associated diarrhoea among patients who used 
PPI.9 In healthcare-related settings, PPI use also increases the risk of recurrent C. 
126
difficile infections.5 Another meta-analysis of 11,280 patients, from six studies evaluating 
Salmonella, Campylobacter and other enteric infections, also found an increased risk due to 
acid suppression, with a greater association with PPI than with H
2
-receptor antagonists.8 
Recently, the Dutch National Institute for Public Health and the Environment (RIVM) noticed a 
marked increase in the occurrence of campylobacteriosis associated with increased PPI use 
in the Netherlands.7 
 
The gut microbiota plays an important role in these enteric infections.10–13 Gut microbiota 
can resist or promote the microbial colonization of the gut by C. difficile and other enteric 
infections through several mechanisms that either directly inhibit bacterial growth or 
enhance the immune system.10,11 Moreover, substituting the gut microbiota of diarrhoea 
patients with C. difficile with a healthy microbiota through faecal transplantation has been 
proven to cure C. difficile infection.14 The increased incidence of enteric infections in PPI 
users and the importance of the gut microbiota composition in the development of these 






We studied the effect of PPI use on the gut microbial composition in three independent 
cohorts from the Netherlands. These cohorts together comprise 1815 adult individuals, 
including both healthy subjects and patients with gastrointestinal diseases. Cohort 1 
consists of 1174 individuals who participate in the general population study LifeLines-DEEP 
in the northern provinces of the Netherlands.15 Cohort 2 consists of 300 Inflammatory Bowel 
Disease (IBD) patients from the department of Gastroenterology and Hepatology University 
Medical Center Groningen (UMCG), the Netherlands. Cohort 3 consists of 189 Irritable Bowel 
Syndrome (IBS) patients and 152 matched controls from Maastricht University Medical 
Center+ (MUMC+), the Netherlands. This study was approved by the institutional review 
boards of the UMCG and the MUMC+ (MUMC+ http://www.clinicaltrials.gov, NCT00775060). 
All participants signed an informed consent form. 
Medication use 
 
Current medication use at the time of stool collection of Cohort 1 participants was extracted 
from a standardized questionnaire.16 Two medical doctors reviewed all the medication for 
1174 participants. PPI use was scored if participants used omeprazole, esomeprazole, 
pantoprazole, lansoprazole, dexlansoprazole or rabeprazole. To exclude other possible drug 
effects on the gut microbiota, medication use was scored in eight categories, allowing for 
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later correction of parameters or exclusion of certain participants. These categories were 
medication that: (1) changes bowel movement or stool frequency, (2) lowers triglyceride 
levels, (3) lowers cholesterol levels, (4) anti-diabetic medication (both oral and insulin), (5) 
systemic anti-inflammatory medication (excluding NSAIDs), (6) topical anti-inflammatory 
medication, (7) systemic antibiotics, including antifungal and antimalarial medication, and 
(8) antidepressants including serotonin-specific reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), mirtazapine, and tricyclic antidepressants (TCAs). 
The definitions of these categories are described in the Supplementary Appendix. Analysis of 
drugs used in Cohort 2 was based on the IBD-specific electronic patient record in the UMCG. 
Current PPI use, as well as current IBD medication (mesalazines, thiopurines, methotrexate, 
steroids, TNF-alpha inhibitors and other biologicals) were scored at the time of sampling by 
the gastroenterologist treating the IBD patient. Current PPI consumption in the IBS case-
control Cohort 3 was based on self-reported questionnaires. Pseudonymized data for all 
three cohorts was provided to the researchers.  
 
Gut complaints and other clinical characteristics 
 
Information on age, gender and BMI was available for all three cohorts. In Cohort 1, 
gut complaints were investigated using an extensive questionnaire that included defecation 
frequency and the Bristol Stool Scale. Possible IBS and functional diarrhoea or constipation 
were determined using self-reported ROME III criteria. The IBD patients in Cohort 2 were 
diagnosed based on accepted radiological, endoscopic, and histopathological evaluation. All 
the IBD cases included in our study fulfilled the clinical criteria for IBD. IBS in Cohort 3 was 
diagnosed by a gastroenterologist according to the ROME III criteria.
 
Stool and oral cavity mucus sample collection  
 
A total of 1815 stool samples and 116 oral cavity mucus samples were collected. Cohorts 
1 and 2 used identical protocols to collect the stool samples. Participants of cohort 1 and 
2 were asked to collect one stool sample at home. Stool samples were frozen within 15 
minutes after stool production in the participants’ home freezer and remained frozen until 
DNA isolation. A research nurse visited all participants to collect the stool samples shortly 
after production and they were transported and stored at –80oC. Participants of cohort 3 were 
asked to bring a stool sample to the research facility within 24 hours after stool production. 
These samples were immediately frozen upon arrival at –80oC. Oral cavity mucus samples 
were collected from 116 additional healthy volunteers using buccal swab. 
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DNA isolation and analysis of microbiota 
composition
 
Microbial DNA from stool samples was isolated with the Qiagen AllPrep DNA/RNA Mini Kit 
cat. # 80204. DNA isolation from oral cavity swabs was performed using the UltraClean 
microbial DNA isolation kit (cat.# 12224) from MoBio Laboratories (Carlsbad, CA, USA). 
To determine the bacterial composition of the stool and oral cavity mucus samples, 
sequencing of the variable region V4 of the 16S rRNA gene was performed using Illumina 
MiSeq. DNA isolation is described in the Methods section of the Supplementary appendix. 
 
Taxonomy determination  
 
Bacterial taxonomy was determined by clustering the sequence reads with UCLUST 
(version 1.2.22q) with a distance threshold of 97%, using Greengenes (version 13.8) as 
the taxonomy reference database. Sequencing and the determination of taxonomy are 




In each cohort, differentially abundant taxa in the gut microbiota between PPI users and 
non-PPI users were analysed using the multivariate statistical framework MaAsLin.17 
MaAsLin performs boosted, additive, general linear models between meta-data and 
microbial abundance data. After running the association studies in the individual cohorts, 
we performed a meta-analysis of the three cohorts, using the weighted Z-score method. 
The Cochran’s Q test was used to check for heterogeneity. The significance cut-off for the 
Cochran’s Q test was determined by Bonferroni correction for the 92 significant results: 
P<5.43x10-4. Differences in richness (the number of species within a sample), principal 
coordinate analyses (PCoA), and Shannon diversity analysis were determined using the 
QIIME microbiome analysis software.18 The Wilcoxon test and Spearman correlations were 
used to identify differences in Shannon’s diversity and relations between the PCoA scores 
of PPI users and non-PPI users, while the Chi-square test, Fisher’s exact test, Spearman 
correlation and Wilcoxon-Mann-Whitney test (WMW test) were used to determine 
differences in age, gender, BMI, antibiotics use, and gut complaints between PPI users and 
non-users. In all the microbiome analyses, multiple test corrections were based on the 
false discovery rate (FDR). An FDR-value of 0.05 was used as a significance cut-off. 
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In addition to the PPI effect, we also tested the influence of other commonly used drugs 
in Cohort 1. Using MaAsLin with similar settings to those described above, we tested the 
microbial changes associated with the use of other drugs, with and without correction for 
PPI, and the changes when including these common drugs as a correcting factor in the PPI 
versus non-PPI analysis. Significant results were graphically represented in cladograms 
using GraPhlAn.19 More details on the statistical analysis can be found in the Methods 
section (Supplementary appendix). 
Correction for factors influencing the gut microbiota 
Differentially abundant taxa were corrected for several parameters, which were identified 
by statistical analysis of cohort phenotypes or univariate MaAsLin runs and subsequently 
added as co-factors to the additive linear model. Analyses in the general population Cohort 
1 were corrected for age, gender, BMI, antibiotics use, sequence read depth, and ROME 
III diagnosis (IBS-Constipation (IBS-C), IBS-Diarrhoea (IBS-D), IBS-Mixed (IBS-M), IBS-
Undetermined (IBS-U), functional bloating, functional constipation, functional diarrhoea, or 
none). The analysis of IBD patients in Cohort 2 was corrected for age, sex, BMI, antibiotics 
use, sequence read depth, diagnosis (Crohn’s disease or ulcerative colitis) combined with 
disease location (colon, ileum or both) and IBD medication (use of mesalazines, steroids, 
thiopurines, methotrexate or anti-TNF antibodies). The analysis of the IBS case-control 
Cohort 3 was corrected for age, gender, BMI, sequence read depth, and IBS status according 
to the ROME III criteria. In the meta-analysis, all microbiome data were corrected for age, 




PPI use is associated to older age and higher BMI 
 
PPI were used by 211 (11.6%) of the 1815 participants: 8.4% of the general population 
(Cohort 1), 20.0% of the IBD patients (Cohort 2) and 15.2% of the participants of case-control 
Cohort 3. Women use PPI more often than men: 9.2% versus 7.4%, albeit this was not 
significant (P = 0.61, Chi-square test). PPI users were generally older: 51.6 (SD 13.4) versus 
44.4 (SD 14.7) years of age (P = 2.50 x 10-11, WMW test) and have a higher BMI of 26.9 (SD 
5.0) versus 24.9 (SD 4.2) for non-users (P = 1.89 x 10-8, WMW test).  
 
  Table 1. Characteristics of the three independent cohorts in this study 
* unless otherwise stated, BMI = body mass index, IBD = inflammatory bowel disease, IBS = irritable bowel syndrome, 
PPI = Proton Pump Inhibitor, SD = standard deviation, TNF = tumour necrosis factor UMCG  
= University Medical Center Groningen, MUMC = Maastricht University Medical Center 
Cohort 1: LifeLines-DEEP  
(general population) 
Cohort 2: IBD patients
UMCG
Cohort 3: IBS case-control 
MUMC 













Average (SD)* Average (SD)* Average (SD)* Average (SD)* Average (SD)* Average (SD)*
Age 51.94 (13.59) 44.79 (13.58) 50.87 (14.49) 42.45 (14.57) 51.94 (14.27) 44.57 (18.24)
BMI 27.73 (5.10) 25.05 (4.03) 26.14 (5.53) 25.58 (4.72) 26.24 (4.10) 24.16 (4.11)














Antibiotics (%) 2.02% 1.02% 31.67% 16.67% 0.00% 1.73%
IBD (%) 0.00% 0.00% 100.00% 100.00% 0.00% 0.00%
IBS (%) 34.34% 25.77% 0.00% 0.00% 90.38% 49.48%
Diarrhoea (%) 
(IBS-D and functional 
diarrhoea together)
7.07% 4.47% - - 28.4% 17.3%
Average bowel 
movements per day
1.36 (0.53) 1.38 (0.61) - - 1.60 (0.81) 1.92 (1.11)
AntiTNF (%) - - 38.33% 28.75% - -
Mesalazines (%) - - 26.67% 39.58% - -
Methotrexate (%) - - 16.67% 5.42% - -
Steroids (%) - - 30.00% 20.42% - -
Thiopurines (%) - - 21.67% 37.08% - -
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Antibiotics were concomitantly used by 2% of the 99 PPI users of Cohort 1 and 33% of the 
60 PPI users of Cohort 2. There was no overlap between PPI users and antibiotics users in 
Cohort 3. Based on our data, we included age, gender, BMI and antibiotics as co-factors in the 
microbiome analyses. Table 1 provides an overview of the characteristics per cohort and the 
use of PPI.
 
Composition of the gut microbiota 
 
The predominant phylum in each cohort was Firmicutes with abundances of 76.7%, 73.8% 
and 77.4% in Cohorts 1, 2 and 3, respectively. Information on the composition of the gut 
microbiota for all three cohorts and on all taxonomic levels is provided in Supplementary 
figures S1, S2 and Supplementary table S1. Independent of PPI use, the overall high-level 
bacterial composition of the gut was homogeneous in all three cohorts (by phylum, class, and 
order level, Spearman correlations: rho>0.94; P<1.6x10-13). 
Reduced diversity of the gut microbiome associated with PPI use
In all three cohorts we identified a lower species richness and lower Shannon diversity, 
although not significant (Cohort 1, P=0.85 ; Cohort 2, P=0.16; Cohort 3, P=0.53), however in 
combined analysis of all three datasets we identified moderate but significant decrease in 
gut alpha diversity of PPI users was observed in the meta-analysis of all 1815 gut microbiota 
samples: Shannon index (P=0.01) and species richness (P=0.02)(Supplementary figures S3 
and S4). 
 
Meta-analysis: differences in gut microbiome 
associated to PPI use
 
The meta-analysis across all three cohorts showed statistically significant alterations in 92 
of the 460 bacterial taxa abundance (FDR<0.05). These changes are depicted in a cladogram 
in Figure 1 and in a heatmap in Figure 2, and in Supplementary figure S5. Details of each 
taxon, including the individual direction, coefficient, P-value and FDR for each cohort, as well 
as the meta-analysis, are provided in Supplementary tables S2 and S3. Cochran’s Q test 
was used to check for heterogeneity. None of the 92 reported associations were significantly 
heterogeneous at the Bonferroni corrected P-value cut off (P<5.43x10-4) (Supplementary 
table S2).  
The overall difference of the gut microbiome associated to PPI use was also observed in the 
PCoA of all the datasets together (Figure 3 and Supplementary figure S6). The same PCoA 
with separate colours for each cohort has been added in Supplementary figure S7. Notably, 
we observed statistically significant differences between PPI users and non-users in two 
principal coordinates (PCoA1: P=1.39x10-20, PCoA3: P=0.0004, Wilcoxon test).
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 Figure 1. PPI-associated statistically signifi cant diff erences in the gut microbiome
Meta-analysis of three independent cohorts comprising 1815 faecal samples, showing a 
cladogram (circular hierarchical tree) of 92 signifi cantly increased or decreased bacterial taxa 
in the gut microbiome of PPI users compared to non-users (FDR<0.05). Each dot represents a 
bacterial taxon. The two most inner dots represent the highest level of taxonomy in our data: the 
kingdoms Archea and Bacteria (prokaryotes), followed outwards by the lower levels: phylum, 
class, order, family, genus and species. Red dots represent signifi cantly increased taxa. Blue dots 
represent signifi cantly decreased taxa.
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 Figure 2. Signifi cantly altered families in PPI users consistent in three cohorts
Meta-analysis of three independent cohorts comprising 1815 faecal samples. The heatmap 
shows 19 families signifi cantly increased or decreased associated with PPI use in the gut 



































Similar changes in three independent cohorts  
were associated to PPI use
The order Actinomycetales, families Streptococcoceae, Micrococcoceae, genus Rothia, and 
species Lactobacillus salivarius were increased in participants using PPI in each cohort. 
None of the individual cohorts contained any significantly decreased taxa (FDR<0.05). In 
the general population (Cohort 1), 41 of the 829 bacterial taxa were significantly increased, 
including the class Gammaproteobacteria, the family Enterococcoceae, and the genera 
Streptococcus, Veillonella and Enterococcus (FDR<0.05) (Supplementary Table S4). No 
effects due to PPI dosage were observed in the associated bacteria. In IBD patients (Cohort 
2), PPI use was associated with an increase of 12 of the 667 bacterial taxa, including the 
family Lactobacillaceae as well as the genera Streptococcus and Lactobacillus (FDR<0.05) 
(Supplementary Table S5). In IBS case-control Cohort 3, 18 of the 624 taxa were 
significantly increased, including the order Lactobacillales (FDR<0.05) (Supplementary 
table S6). 
 
Oral cavity bacteria are more abundant in  
the gut microbiota of PPI users
We hypothesized that the changes in the gut microbiota associated with PPI use are caused 
by reduced acidity of the stomach and the subsequent survival of more bacteria that are 
ingested with food and oral mucus. Indeed, some of the statistically significantly increased 
bacteria in PPI users (e.g. Rothia dentocariosa, Rothia mucilaginosa, the genera Scardovia and 
Actinomyces and the family Micrococcaceae) are typically found in the oral microbiota.20 By 
analysing 116 oral microbiota samples from participants in Cohort 1, we could compare 
the overall composition of bacteria in the oral microbiota to the composition of the gut 
microbiota. We observed a statistically significant shift in Principal Coordinate 1 in the gut 
microbiome samples of the PPI users towards the oral samples, compared to non-PPI users 
(P=1.39x10-20, Wilcoxon test) (Figure 3). In Supplementary figure S8, the overrepresentation 
of oral cavity bacteria in the guts of PPI users is depicted in a cladogram.
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 Figure 3. Principal Coordinate Analysis of 1815 gut microbiota samples 
 and 116 oral microbiota samples. 
Principal Coordinate Analysis: The gut microbiome of PPI users is signifi cantly diff erent to non-PPI 
users in the fi rst Coordinate (PCoA1: P=1.39x10-20, Wilcoxon test). For Principal Coordinate 1 there 

















PPI use is independent of bowel movement  
frequency and stool consistency
Some of the significantly increased taxa were more abundant in the small intestine.11 To 
ensure that the changes observed in microbiota composition were not due to diarrhoea 
and/or more frequent bowel movements, we checked in our general population whether 
clinical symptoms of diarrhoea were more often present in PPI users. Neither diarrhoeal 
complaints (IBS-D and functional diarrhoea, P=0.22, Fisher’s exact test), stool consistency 
as defined by the Bristol Stool Scale (rho=0.027 P=0.36, Spearman correlation) nor the 
defecation frequency (rho=-0.001, P=0.98, Spearman correlation) of the participants in 
Cohort 1 were related to PPI use.
 
 
PPI, antibiotics and other commonly 
used drugs
In Cohort 1, sixteen taxa were associated to antibiotics and others commonly used drug 
categories besides PPI (Supplementary table S7). After correction for PPI use, only 
six taxa remained associated to certain drugs: statins, fibrates and drugs that change 
bowel movements. All 92 alterations in bacterial taxa associated to PPI use remained 
statistically significant if we correct the microbiome analyses for antibiotics and other 






We show that PPI use is consistently associated with profound changes in the gut 
microbiota. In our study these changes were more prominent than changes associated 
with either antibiotics or other commonly used drugs. While PPI have proven to be useful 
in the prevention and treatment of ulcers and GERD, they have also been associated with 
an increased risk of C. difficile, Salmonella spp., Shigella spp., Campylobacter spp., and other 
enteric infections.4,5,7–9 The increased risk of acquiring one of these enteric infections is 
likely due to changes in the PPI user’s gut microbiota. Gut microbiota can resist or promote 
colonization of C. difficile and other enteric infections through mechanisms that either 
directly inhibit bacterial growth or enhance the immune system.10–13 In the case of C. difficile, 
spores might be able to germinate more easily because of metabolites synthesized by 
certain gut bacteria.12,13
We hypothesized that PPI change the gut microbiota through their direct effect on 
stomach acid. This acidity forms one of the main defences against the bacterial influx 
that accompanies ingesting food and oral mucus. PPI reduce the acidity of the stomach, 
allowing more bacteria to survive this barrier. We have shown here that species in the oral 
microbiota are more abundant in the gut microbiota of PPI users. Moreover, a study looking 
into the effect of PPI on the oesophageal and gastric microbiota in oesophagitis and Barret’s 
oesophagus showed similar bacterial taxa associated with PPI use, including increased 
levels of Enterobacteriaceae, Micrococcaceae, Actinomycetaceae and Erysipelotrichaceae.21 
Gastric bypass surgery compromises the stomach acid barrier and leads to gut microbiota 
changes similar to the PPI-associated alterations in this study, thereby supporting our 
hypothesis.22
 
We looked at the role of the gut microbiota in C. difficile infections, which cause 12.1% of 
all nosocomial infections and were responsible for half a million infections and associated 
with 29,000 deaths in the United States in 2011.23,24 Virulent strains of C. difficile can only 
colonize a susceptible gut, after which toxins are produced and spores are shed. This 
leads to a wide spectrum of symptoms varying from mild diarrhoea to fulminant relapsing 
diarrhoea and pseudomembranous colitis.25 Recent human, animal and in vitro studies 
show an overlap between the specific alterations in the gut microbiota associated with 
PPI use found in this study and bacterial changes that lead to increased susceptibility to C. 
difficile. The reduced alpha diversity in PPI-users is associated with increased susceptibility 
to C. difficile infection.13,27,28 The PPI-associated decreases of the family Ruminococcoceae 
and the genus Bifidobacterium, as well as the PPI-associated increases of the class 
Gammaproteobacteria, the families Enterobacteriaceae, Enterococcoceae, Lactobacillaceae 
and the genera Enterococcus and Veillonella, have been consistently linked to increased 
susceptibility to C. difficile infection. (Table 2)10,13,26–32 
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The Ruminococcoceae family is significantly decreased in C. difficile patients and enriched 
in healthy controls.28,29,31 Moreover, mice that have been treated with a mixture of antibiotics 
that do not become clinically ill after a challenge with C. difficile have higher levels of 
Ruminococcaceae.26 Within the Ruminococcaceae family, the Faecalibacterium genus 
was significantly increased in patients who recovered from C. difficile illness, whereas 
it was severely decreased in C. difficile patients with active disease.31 Last, a decreased 
Ruminococcus torques OTU was significantly associated with C. difficile infection in another 
study, although their OTU-picking was done using a different reference database and 
associations were performed using OTU-level, making direct comparisons with our study 
difficult.13
 
Species of the Bifidobacterium genus: Bifidobacterium longum, Bifidobacterium lactis, 
Bifidobacterium pseudocatenulatum, Bifidobacterium breve, Bifidobacterium pseudolongum, 
Bifidobacterium adolescentis and Bifidobacterium animalis lactis have been shown to 
inhibit or prevent C. difficile infection.10 The administration of antibiotics that enhance 
the susceptibility to C. difficile in an in vitro model of the gut also significantly reduce the 
genus Bifidobacterium.30 Moreover, active C. difficile diarrhoea is associated with decreased 
Bifidobacteria in elderly patients.29 
The class Gammaproteobacteria and the family Enterobacteriaceae are both significantly 
increased in PPI users. Gammaproteobacteria are enriched in C. difficile patients compared 
to healthy controls.28 Within the class Gammaproteobacteria, the family Enterobacteriaceae 
dominate the murine gut microbiota after administration of clindamycin. Those mice that 
became clinically ill after the administration of an antibiotic cocktail containing clindamycin 
and a C. difficile challenge, had profoundly increased levels of Enterobacteriaceae in their 
gut microbiota, while mice that did not become clinically ill had a gut microbiota that 
predominantly consisted of Firmicutes.26 The family Enterobacteriaceae is also increased in 
hamsters that were treated with clindamycin and subsequently infected with C. difficile.32
The Enterococcus genus, which is also more abundant in PPI-users, is significantly enriched 
in C. difficile-infected patients compared to healthy controls.28,31 An Enterococcus faecalis 
OTU and an Enterococcus avium OTU are both significantly associated with increased 
susceptibility to C. difficile infections in mice.13 Moreover, an Enterococcus avium OTU is also 
significantly associated with C. difficile in humans.13 The administration of the antibiotic 
ceftriaxone lead to an increase in the genus Enterococcus and enhanced the susceptibility to 
C. difficile in an in vitro model of  
the gut.30
 
The increased abundance of the family Lactobacillaceae in PPI users was associated 
with increased risk of C. difficile infection in several studies. Mice treated with a cocktail of 
antibiotics (consisting of kanamycin, gentamycin, colistin, metronidazole and vancomycin), 
cefoperazone or a combination of clindamycin and cefoperazone have higher levels of 
Lactobacillaceae in their gut.26 Mice treated with cefoperazone and clindamycin that 
developed C. difficile infection after being challenged with the pathogen also had a higher 
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level of Lactobacillaceae.26 Within the Lactobacillaceae family, the Lactobacillus genus 
is significantly enriched in C. difficile infection patients compared to healthy controls.28 
Lactobacillus spp in the gut microbiota are also associated with active C. difficile diarrhoea 
in patients. 29 In contrast to these studies, the Lactobacillus species Lactobacillus delbrueckii, 
Lactobacillus plantarum and a Lactobacillus reuteri OTU increased colonization resistance 
to C. difficile.10,13 However, in concordance with increased risk, a Lactobacillus johnsonii OTU 
enhanced C. difficile infection.13 
Last, the Veillonella genus that is increased in PPI users is significantly enriched in C. difficile 
patients compared to healthy controls.28  
The prevention of healthcare-associated C. difficile infections is a priority in the United 
States and reduction targets for 2020 have been established.5,33 A recent study looking 
into the effect of PPI on the risk of developing recurrent C. difficile infections found that 
of 191 PPI users admitted to a hospital, only 47.1% had an evidence-based indication for 
PPI use.5 Moreover, PPI use was discontinued in only 0.6% of the cases.5 The U.S. Food 
and Drug Administration already recommends limiting PPI use to a minimum dose and 
duration.34 Despite these recommendations, PPI are still often over-prescribed.5,6 The risk of 
unnecessary antibiotics use is already addressed.35 However, limiting the unnecessary use 
of PPI should also be considered in preventing C. difficile and other enteric infections.
The microbiota is being intensively studied in various diseases and conditions including 
IBD, IBS, obesity, old age, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver 
disease (NAFLD).36 PPI users are overrepresented in these groups as they more likely to 
have gastrointestinal complaints or experience GERD, either due to their health condition 
or their associated lifestyle. Prominent microbiome studies looking into obesity, IBD and 
NAFLD include results that researchers have contributed to the condition under study, but 
we show they are also associated to PPI use.17,37 It could well be that some of the observed 
effects should rather have been attributed to the use of PPI. Future microbiome studies in 
humans should therefore always take the effect of PPI on the gut microbiota into account. 
This paper reports the largest study to date investigating the influence of Proton Pump 
Inhibitors on the gut microbiota. The profound alterations seen in the gut microbiota 
could be linked to the increased risk of C. difficile and other enteric infections. Given the 
widespread use of PPI, the morbidity and mortality associated with enteric infections, 
and the increasing number of studies investigating the microbiome, both healthcare 
practitioners and microbiome researchers should be fully aware of the influence of PPI on 
the gut microbiota.
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PPI, proton pump inhibitor. 
k__, kingdom; p__, phylum; c__, class; o__, order; f__, family; g__, genus; s__, species 
associations are in bold
 Table 2. Taxa and microbiota aspects associated with both PPI use and increased risk of C.  
 difficile infection
Taxa or microbiota aspect Direction in PPI users 
that increases the risk 
of C. difficile infection
References of role on risk of C. difficile infection.
Alpha diversity Reduced 13 Buffie et al. Nature. 2015  
27 Chang et al. J. Infect. Dis. 2008 






Decreased 26 Reeves et al. Gut Microbes. 2011 
28 Antharam et al. Journal of Clinical Microbiology. 2013. 
13 Buffie et al. Nature. 2015. Extended Figure 3d and 3e 
31 Schubert et al. Mbio. 2014. 







Decreased 10 Buffie et al. Nature Reviews Immunology. 2013 
29 Rea et al. Journal of Clinical Microbiology. 2011 







Increased 28 Antharam et al. Journal of Clinical Microbiology. 2013 
31 Schubert et al. Mbio. 2014 
29 Rea et al. Journal of Clinical Microbiology. 2011 (Figure 4) 
13 Buffie et al. Nature. 2015 (Extended figure 3d and 3e) 










Increased 26 Reeves et al. Gut Microbes. 2011 
28 Antharam et al. Journal of Clinical Microbiology. 2013 
29 Rea et al. Journal of Clinical Microbiology. 2011 
10 Buffie et al. Nature Reviews Immunology. 2013 















Increased 28 Antharam et al. Journal of Clinical Microbiology. 2013 
26 Reeves et al. Gut Microbes. 2011 
31 Schubert et al. Mbio. 2014 
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Campylobacter bacteria as seen from an electron microscope. Campylobacter bacteria are enteric, curved-rod 
prokaryotes that cause campylobacteriosis, one of the most common bacterial causes of diarrheal illness. 
It is a relatively fragile bacterium that is easily killed by cold or hot temperatures. Birds are carriers due to 
their body temperature being just right to host the bacteria. Improper handling of raw poultry or undercooked 
fowl is usually the source of infection in humans. According to the National Institute for Public Health and the 
Environment (RIVM), the incidence of campylobacteriosis follows the exact same trend as the number of PPI 
prescriptions in the Netherlands. Credit: De Wood; digital colorization by Chris Pooley
